Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Fineline Cube Apr 13, 2026
Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Fineline Cube Apr 13, 2026
Company Medical Device

United Imaging’s uMR Jupiter 5T Becomes First Ultra-High Frequency MRI System to Gain FDA Approval

Fineline Cube May 6, 2024

Shanghai-based medical equipment manufacturer United Imaging Healthcare (UIH, SHA: 688271) has announced that it has...

Company Drug

HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion

Fineline Cube May 6, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...

Company Drug

Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China

Fineline Cube May 6, 2024

Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Deals Medical Device

Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent

Fineline Cube May 6, 2024

Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...

Company

Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase

Fineline Cube May 6, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...

Company

Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft

Fineline Cube May 6, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...

Company Drug

Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO

Fineline Cube May 6, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...

Company Drug

BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China

Fineline Cube May 6, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...

Company Medical Device Policy / Regulatory

China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics

Fineline Cube May 6, 2024

The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...

Company Drug

China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication

Fineline Cube May 6, 2024

Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...

Company Deals

Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing

Fineline Cube May 6, 2024

Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...

Company

Hainan Poly Pharm’s Manufacturing Units Get GMP Nod From Saudi Food and Drug Authority

Fineline Cube May 6, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...

Policy / Regulatory

GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises

Fineline Cube Apr 30, 2024

The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...

Company Drug

Keymed Biosciences’ IL-4Rα Monoclonal Antibody for Allergic Rhinitis Accepted by China NMPA

Fineline Cube Apr 30, 2024

China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that the National Medical Products...

Company Drug

Bristol-Myers Squibb’s Camzyos Approved by China’s NMPA for Hypertrophic Cardiomyopathy Treatment

Fineline Cube Apr 30, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has received marketing approval from China’s National Medical Products Administration...

Company Drug

Cutia Therapeutics Submits New Drug Application for Androgenic Alopecia Treatment in Hong Kong

Fineline Cube Apr 30, 2024

Cutia Therapeutics (HKG: 2487), a dermatology-focused pharmaceutical company, has announced the submission of a New...

Company Drug

Zhejiang Huahai Pharmaceutical Wins IND Approval for Antibody-Drug Conjugate from China’s NMPA

Fineline Cube Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...

Company R&D

German Study Highlights Potential of Amgen’s Blinatumomab in Treating Rheumatoid Arthritis

Fineline Cube Apr 30, 2024

Researchers from Germany’s University of Erlangen-Nuremberg have unveiled promising clinical data on the use of...

Company Legal / IP

U.S. Judge Dismisses Johnson & Johnson and Bristol-Myers Squibb Lawsuits Against Drug-Pricing Provisions in Inflation Reduction Act

Fineline Cube Apr 30, 2024

In a recent legal development, a U.S. federal court judge has rejected the legal challenges...

Company Deals

Sino Biological Inc. to Acquire Canadian Bioactive Enzyme Manufacturer SignalChem Biotech

Fineline Cube Apr 30, 2024

Sino Biological Inc. (SHE: 301047), a leading provider of biological research reagents and technical contract...

Posts pagination

1 … 350 351 352 … 649

Recent updates

  • CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
  • Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
  • Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
  • Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine

Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Company Drug

Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines

Company Drug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.